SEHK:512Pharmaceuticals
Grand Pharmaceutical Group (SEHK:512): Valuation Insights Following Key Liver Cancer Drug Clinical Milestone
Grand Pharmaceutical Group (SEHK:512) has completed patient enrollment for its China registration clinical study of GPN00289, a next-generation embolic agent targeting primary liver cancer. This product represents an important step in expanding the company's oncology pipeline.
See our latest analysis for Grand Pharmaceutical Group.
It has been a transformative year for Grand Pharmaceutical Group, with its latest clinical milestone reflecting sustained momentum. The stock’s 84.33% total return...